Neurogene Inc.
NGNE
$19.98
-$0.01-0.05%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -100.00% | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -100.00% | -- | -- | -- | -- |
| Cost of Revenue | 29.77% | 36.95% | 37.01% | 33.47% | 24.90% |
| Gross Profit | -32.08% | -35.01% | -34.93% | -31.33% | -22.72% |
| SG&A Expenses | 61.14% | 86.72% | 102.10% | 79.30% | 82.52% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 37.29% | 48.07% | 50.12% | 42.49% | 35.13% |
| Operating Income | -39.14% | -46.56% | -48.45% | -40.77% | -33.33% |
| Income Before Tax | -77.27% | -97.36% | -106.91% | -4.50% | 2.70% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -77.27% | -97.36% | -106.91% | -4.50% | 2.70% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -77.27% | -97.36% | -106.91% | -4.50% | 2.70% |
| EBIT | -39.14% | -46.56% | -48.45% | -40.77% | -33.33% |
| EBITDA | -41.36% | -49.42% | -51.60% | -43.70% | -35.73% |
| EPS Basic | -109.25% | -120.71% | 30.90% | 187.02% | 178.44% |
| Normalized Basic EPS | 92.35% | 94.68% | 96.08% | 72.15% | 5.06% |
| EPS Diluted | 86.38% | 92.38% | 94.93% | 99.71% | 46.66% |
| Normalized Diluted EPS | 87.85% | 92.86% | 95.16% | 95.45% | 40.23% |
| Average Basic Shares Outstanding | 124.63% | 303.31% | 3,471.62% | 635.91% | 194.76% |
| Average Diluted Shares Outstanding | 52.10% | 111.87% | 277.22% | 874.25% | 335.33% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |